

Protecting and improving the nation's health

'The First Few Hundred (FF100)' Enhanced Case and Contact Protocol v4

Epidemiological protocols for comprehensive assessment of Wuhan novel coronavirus (WN-CoV) cases and their close contacts in the United Kingdom

About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health.

Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG

Tel: Irrelevant & Sensitive

www.gov.uk/phe Twitter: @PHE_uk

Facebook: www.facebook.com/PublicHealthEngland

© Crown copyright

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published January 2020 PHE publications gateway number



Contents

About Public Health England	2
Executive summary	4
1.0 Overview of FF100 approach	5
1.1 Introduction and overview1.2 Protocol objectives1.5 Coordination of investigations and review of data1.6 Country-specific adaptation of the protocols	5 5 6 6
2. Methods	8
 2.1 Case and contact definitions 2.1.1 Interim definition: possible cases 2.2 Recruitment and follow-up of confirmed cases and their close contacts 2.4 Data collection on cases and household contacts 2.4.1 Data collection on cases 2.4.2 Data collection on close contacts 2.5 Role of laboratory testing 2.6 Analyses and interpretation of data 	8 10 12 12 12 13 14
3.0 Questionnaires	15
Minimum Dataset form	15
Daily Line list of close contacts of a confirmed case	15
Form 1a (initial form for a confirmed case)	15
Form 1b (follow up form for a confirmed case)	15
Form 2a (initial form for a close contact of a confirmed case)	15
Form 2b (follow-up form for a close contact of a confirmed case)	15
Acknowledgements	53

Executive summary

The epidemiological and virological investigation of the first cases of acute respiratory infection associated with Wuhan novel coronavirus (WN-CoV) and their close contacts is essential in order to inform guidance and policy in directing the United Kingdom's (UK) public health response. Note that other sources use the tempoarary name of 2019 novel coronavirus (2019-nCoV) in the absence of an internationally accepted term at this present time.

The epidemiological methods to guide data collection for the comprehensive assessment of the 'first few hundred cases and their close contacts' are set out in this document. The protocol outlines the investigation of persons with laboratory confirmed WN-CoV infection, along with their close contacts.

1.0 Overview of FF100 approach

1.1 Introduction and overview

On 31 December 2019, WHO was notified of a cluster of unexplained pneumonia cases detected in Wuhan city, Hubei province in China. On 7 January 2020 Chinese authorities identified a novel coronavirus, currently designated as WN-CoV by PHE, (also known as 2019-nCoV), using genetic sequencing from an isolate in a hospitalised patient. The number of confirmed cases (which includes health care workers) has been rising in China with detections being reported in travellers to other countries. There is concern of international spread. This is an evolving situation. Ongoing epidemiological information is being shared between countries to understand geographical spread and severity.

With the confirmation of WN-CoV, the epidemiological and virological investigation of the initial imported cases in the UK and their close contacts is essential to provide information to enable the development of guidance and policy in directing the United Kingdom's (UK) public health response.

A flexible and multifaceted approach is required to collect key epidemiological, clinical and virological data on cases.

1.2 Protocol objectives

The overall aim of the FF100 is to gain an early understanding of some of the key clinical, epidemiological, and virological characteristics of the first suspected and confirmed cases. Additionally, the system updates national policy and guidance to manage cases and reduce the spread and impact of infection in the UK.

The primary objectives are to provide estimates of:

- clinical presentation and course of disease
- secondary attack rate (overall and by key factors such as by setting, age and gender for various end-points)¹
- serial interval²

Page 5 of 53

¹ Attack rate is defined as the proportion of a well-defined population that develops illness over a particular period of time. The secondary attack rate is a measure of the frequency of new cases of an illness among the contacts of known cases in a defined period of time.

² Serial interval is defined as the period of time from the onset of symptoms in the index case to the onset of symptoms in a contact case.

proportion of symptomatic cases

The secondary objectives are to provide data to support the estimation of:

- the basic reproductive number (R₀)³.
- incubation period⁴
- preliminary case-severity ratios (eg case-hospitalisation and case-fatality ratios)⁵

This information will be used to refine/update recommendations for surveillance (eg case definitions), to characterise the key epidemiological transmission features of the virus, help understand geographic spread, severity and impact on the community and inform operational models for implementation of countermeasures such as case isolation and contact tracing.

1.5 Coordination of investigations and review of data

Coordination of investigations and sharing of information in real time will be needed at local Health Protection Team, country and UK levels. Public health experts will assess progress in developing early estimates of key epidemiological, clinical and virological parameters.

The responsibility of the FF100 investigations will lie with local Health Protection Teams and the equivalents in the Devolved Administrations. Co-ordination of the system will be undertaken by the PHE Colindale.

The FF100 system will be maintained centrally by PHE Colindale. Centralised coordination at the UK-level will require development of a "command and control" plan to allow for triage and prioritisation of investigations.

1.6 Country-specific adaptation of the protocols

It is envisioned that all countries of the UK will use FF100 protocols to guide their investigations of laboratory confirmed case(s). A common UK approach will facilitate aggregation of data across countries of the UK. However, it is

³ The reproduction number, R_0 , is defined as the average number of secondary cases of an infectious disease that result from one infected person in a wholly susceptible population.

⁴ Incubation period is defined as the period of time between an exposure resulting in infection until the onset of clinical symptoms of disease.

⁵ Case hospitalisation ratio (CHR) is defined as the proportion of those affected (with symptoms) that are admitted to hospital. The case fatality ratio (CFR) is defined as the proportion of those affected who die as a direct or indirect consequence of their infection.

recognised that the devolved UK administrations may need to tailor some aspects of the protocols to their individual public health, laboratory and clinical care systems.

2. Methods

2.1 Case and contact definitions

2.1.1 Interim definition (as of 29 January 2020): possible cases

If the patient satisfies epidemiological AND clinical criteria, they are classified as a possible case of WN-CoV

EPIDEMIOLOGICAL CRITERIA

In the 14 days days before the onset of illness:

- travel to Wuhan, Hubei Prorovince, China OR
- Contact (see definition below) with a confirmed cases of 2019-nCoV

CLINICAL CRITERIA

 severe acute respiratory infection requiring admission to hospital with clinical or radiological evidence of pneumonia or acute respiratory distress syndrome (ARDS)

OR

 acute respiratory infection of any degree of severity (including at least one of: shortness of breath, cough or sore throat)

Clinicians should be alert to the possibility of atypical presebtations in patients who are immunocompromised

For up the latest case definition see:

https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection

2.1.2 Case classification:

A. Possible case

A patient that satisfies epidemiological AND clinical criteria as set out in section 2.1.1

B. Confirmed case

(PHE-Respiratory Virus Unit) positive PCR confirmation of infection with WN-CoV (also known as 2019-nCoV)

C. Discarded case

Any possible case with a negative laboratory result for WN-CoV (also known as 2019-nCoV)

2.1.3 Contact classification:

Close contact definitions:

A close contact of a case is defined as

- Household contact: living or significant time in the same household
- Healthcare contacts: Persons in healthcare settings (e.g. healthcare workers, visitors) or laboratory workers in direct contact with the case or their bodily fluids or their laboratory specimens or in the same room as a case in a healthcare setting when an aerosol generating procedure is undertaken on the case.
- Flight contact: Passengers in 2 seats in all directions around the case AND Cabin crew serving the area where case seated
- Other close contacts: Direct contact or face to face contact with case e.g. talking, being coughed on for any length of time OR being ≤2 metres of the case for >15 minutes.

All persons meeting the close contact definition should be notified to the local Health Protection Team (HPT). The HPT should discuss with the National Infections Service (NIS)

2.1.4 Other classifications:

A. Primary case: A primary case is defined as an individual who tests positive for WN-CoV by the PHE reference laboratory and has the earliest onset date in a particular setting eg hospital, household, school, etc. Those cases with onset dates within 24 hours of the onset date of the index case are considered to be "co-primary" cases.

2.1.4 Other classifications:

A. Primary case: A primary case is defined as an individual who tests positive for WH-CoV by the PHE reference laboratory and has the earliest onset date in a particular setting eg hospital, household, school, etc. Those cases with onset dates within 24 hours of the onset date of the index case are considered to be "co-primary" cases.

- **B. Secondary case:** After excluding the primary / co-primary cases, a secondary case is defined as the contact whose onset date is 24 hours or more after the latest onset date of the primary and/or co-primary case-contact and confirmed positive for WN-CoV.
- **C. Sporadic case:** A sporadic case is defined as a case confirmed positive for WN-CoV with no recent travel (in the 14 days before disease onset) from a known affected area and no recent (in 14 days before disease onset) close contact with a confirmed case.
- **D: Imported case:** An imported case is defined as a case confirmed positive for WN-CoV with a history of travel from an affected area as defined below in the 14 days before disease onset.
- **E. Affected area:** An affected area is a country/region having had recent confirmed WN-CoV which is not import related

2.2 Recruitment and follow-up of confirmed cases and their close contacts

For instructions regarding the management and sampling of cases please refer to https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection

The HPT will begin to collect core information on notified possible cases using the **Minimum Data Set Form 1** (Section 3). This should be emailed to respiratory.lead@phe.gov.uk.

FF100 case-contact investigation by the HPT would begin on identification of a of a confirmed case by the PHE Respiratory Virus Unit (RVU) lab.

Confirmed cases identified as part of individual-case investigations will serve as the starting point for contact investigations. A list of close contacts should be identified and collated using the contact line list by the PHE HPT (Page 16) and emailed to PHE Colindale pending results of confirmatory testing by the PHE National

Reference Laboratory. Efforts should be made to identify every close contact at the initial recruitment including infants and children to generate the sampling frame for follow up. This line list should be reviewed on a daily basis and sent to PHE Colindale daily.

Cases should be interviewed as rapidly as possible after confirmation by PHE National Reference Laboratory (Form 1a) and then 14 days (Form 1b) after completion of Form1a. Information on the primary case and their close contacts at the initial recruitment should be sought through a combination of face-to-face and/or telephone interview of the case (or family members if the case is too ill to be interviewed), household members, interview of health care providers and/or review of medical records where required.

Baseline samples should be collected on confirmed cases as soon after confirmation as possible and full PPE should be worn. For details regarding the type and transport of these samples please refer to the PHE lab guidance and infection control advice. Follow up samples from cases should be taken after discussion with the PHE Colindale incident control team, and sent to PHE National Reference Laboratory—please see lab guidance here.

Active follow-up of contacts should take place ideally through face-to-face or telephone interview ideally as soon as possible after identification of a confirmed case to query about the possible development of respiratory illness using **Form 2a**. Detailed information on the Close Contact management guidance for WN-CoV (also known 2019-nCoV) will be published on PHE's Duty Doctor pack shortly.

If the contact is ill with acute respiratory symptoms that developed within 14 days of exposure with confirmed case they should be treated as a symptomatic contact. Please refer to the Close Contact management guidance for WN-CoV (to be published on PHE's Duty Doctor pack) for further details about how to deal with symptomatic contacts and the respiratory and serological samples required. NB If there is no possibility of laboratory confirmation because the patient or samples are not available and the symptoms are not explained by any other infection or aetiology, the symptomatic contact becomes a possible case. Please follow Infection control guidance in handling the contact.

If the contact is not ill with acute respiratory symptoms that developed within 14 days of exposure with confirmed case then complete **Form 2b** 14 days after last exposure.

Contacts found to be infected with WN-CoV (or referred to as 2019-nCoV) as determined by PHE National Reference Laboratory testing would be re-classified as confirmed cases and case follow-up forms would be completed (Form 1a and

1b). Guidance on the management of confirmed cases is available and should be followed.

2.4 Data collection on cases and household contacts

2.4.1 Data collection on cases

Further guidance on the completion of FF100 forms can be found in Appendix A, including additional sources of data to be used for verification. Questionnaires can be found in Section 3 of this document. Field services are allowed to create their own contact ID as long as the ID is consistently linked with the individual. The following questionnaires are used:

Minimum Data Set Form 1 (Section 3) should be completed for all possible cases on identification and emailed to PHE Colindale (respiratory.lead@phe.gov.uk).

The Initial Confirmed Case Report Form 1a (Section 3) should be completed as soon as possible after PHE Respiratory Virus Unit (RVU) confirmation of a case and includes the following information: identifiers, basic demographic information, presenting illness, antiviral use, hospitalisation details, pre-existing medical conditions, exposure history and details of household and other close contacts. This form should be emailed to PHE Colindale (respiratory.lead@phe.gov.uk).

The Case Follow-up Form 1b (Section 3) should then be completed once the 14 day follow up period has been completed. The form will gather information including identifiers; hospitalisation details; illness characteristics; death details; treatment with antivirals and antibiotics; clinical course and complications including details of secondary bacterial complications. This form should be emailed to PHE Colindale (respiratory.lead@phe.gov.uk). Collection of convalescent clotted blood/serum samples should be arranged at least 14 days after the first sample.

2.4.2 Data collection on close contacts

The key activities for the initial investigation of close contacts are:

 Verification of close contacts of the index case patient and completion of contact line list (Section 3). The line list should be collated by the local Field Service and emailed to PHE Colindale (respiratory.lead@phe.gov.uk) when the a confirmed case is identified. This line list should be updated daily and updates sent to PHE Colindale.

Determination if each contact is ill, including dates of onset. If confirmed and onset is prior to the index case will require reclassifying the primary case. Any

contact with acute respiratory symptoms within 14 days of last exposure with the case should be treated as a symptomatic contact. Please refer to the Close Contact management guidance for WN-CoV (to be published on PHE's Duty Doctor pack shortly).

- Collection of baseline information from close contacts (Initial Contact Report Form 2a (Section 3)) of a confirmed case including information about exposures to the confirmed case, illness and treatment (if applicable), and medical history. This form should be emailed to PHE Colindale (respiratory.lead@phe.gov.uk). For household contacts and other contacts in closed settings collection of baseline clotted blood samples should be arranged (contact IMT epi cell for advice). This should occur on the day of first interview of confirmed case where possible, or as soon after as possible.
- Contacts should be informed to report any respiratory illness to their local PHE
 Health Protection team following completion of Form 2a. Please refer to the
 Close Contact management guidance (to be published on PHE's Duty Doctor
 pack shortly) about how to deal with symptomatic contacts.
- The Contact Follow Up Form 2b (Section 3) should be completed 14 days since last exposure with confirmed case. The Contact Follow-up Form includes information about exposures to the primary case, and if any recent respiratory illness. This form should be emailed to PHE Colindale (respiratory.lead@phe.gov.uk). For household contacts and other contacts in closed settings collection of baseline clotted blood samples should be arranged (contact IMT epi cell for advice).
- Contacts found to be infected with WN-CoV as determined by PHE National Reference Laboratory testing would be re-classified as confirmed cases and follow-up would occur as described in the case investigation algorithm.

The FF100 web tool will soon be available to local PHE centres to facilitate data entry of the completed forms.

2.5 Role of laboratory testing

A real time PCR test for WN-CoV is not currently available in PHE's Respiratory Virus Unit or designated PHE testing laboratory and the three Devolved Administrations. Currently a confirmed case is based on a possible case being positive for pancoranvirus and and subsequently sequenced.

The Respiratory Virus Unit will also request further follow-up samples for investigation (eg BAL, EDTA blood, faeces, urine, clotted blood/serum) from a WN-CoV confirmed patient. All samples submitted should be urgently transported to the

Respiratory Virus Unit Colindale in accordance with Cat B transportation regulations. PHE follows the Guidance on regulations for the transport of infectious substances 2013-2014, published by WHO (http://www.who.int/ihr/publications/who_hse_ihr_2012.12/en/). Details on sampling and transportation are available here.

2.6 Analyses and interpretation of data

A descriptive analysis of the FF100 should provide preliminary insight into the clinical spectrum and course of disease; the population groups most affected initially, by age, and underlying risk factors for example. It may also be possible to assess the effect of antiviral treatment on severity measures such as duration of illness.

3.0 Questionnaires

Pages 16-17: Minimum Dataset form

Pages 18: Daily Line list of close contacts of a confirmed case

Pages 19-28 : Form 1a (initial form for a confirmed case)

Pages 29-34: Form 1b (follow up form for a confirmed case)

Pages 35-44: Form 2a (initial form for a close contact of a confirmed case)

Pages 45-50: Form 2b (follow-up form for a close contact of a confirmed case)

Minimum Data Set Form 1 (page 1 of 2) – Possible Case

Minimum Dataset Form v7- Wuhan

Local Case no.			Case No. (For Colindale					
(if applicable)			use)					
*Mandatory fields in	n pink with bo 1. Current Sta		n asterisk					
*Please mark x	Alive	itus	Dead					
Is this a contact of a previously reported case?	Yes	No	Unknown					
2	. Reporter De	tails						
*Name of the reporter (person completing the form)	-							
Organisation								
Phone and extension								
Mobile								
Email								
Date Reported								
Date of interview with informant								
	3. Patient Det	ails						
*Forename								
*Surname								
NHS Number								
*Sex	Male	Female	Unknown					
*Date of Birth			Age					
Local ID Number (HPZone number)			Post Code					
*PHEC/ DA managing the case:								
	Presenting II	Iness						
Date of first symptom onset								
Fever or history of Fever (≥38°C)	Yes	No	Unknown					
Cough	Yes	No	Unknown					
Shortness of breath	Yes	No	Unknown					
Sore throat	Yes	No	Unknown					
*Clinical suspicion of pneumonia (or ARDs) ¹	Yes	No	Unknown					
Respiratory viral screen:	Yes	No	Unknown					
Influenza A	Positive	Negative	Not tested					
If Influenza A positive	H1	H3	H5	H7				
•	Untypeable							
Influenza B	Positive	Negative	Not tested					
RSV	Positive	Negative	Not tested					
Other respiratory viruses (please specify)								
	Other pathoge	ens:						
Legionella		Negative	Not tested					
Other (please specify)		-						

Communications to PHE should only be sent between PHE email addresse

Page **16** of **53**

Minimum Data Set Form 1 (page 2 of 2) – Possible Case

Minimum Dataset Form v7- Wuhan

5. Clinical Course/Complications							
Admitted to hospital	Yes	No	Unknown				
Name of hospital		2	•				
Admitted to ICU/HDU	Yes	No	Unknown				
Mechanical ventilation	Yes	No	Unknown	1.4			
ECMO ²	Yes	No	Unknown				
Chest x-ray with radiological evidence of pneumonia	Yes	No	Unknown				
6. Exposures in the 1	4 days before	onset of firs	st symptoms				
*History of travel to China in the 14 days before onset of symptoms?	Yes	No	Unknown				
If YES, history of travel to Wuhan city?	Yes	No	Unknown				
If YES, date left Wuhan City							
Date of arrival in UK							
	ith pneumonia nan in 14 days mptom onset?	Yes	No	Unknown			
Contact with confirmed cas in 14 days before sy		Yes	No	Unknown			
	s (within <1m) ina in 10 days mptom onset?	Yes	No	Unknown			
Contact within a confirmed human influenza within Ch before syl	Yes	No	Unknown				
the state of the s		Yes	No	Unknown			
[1] Acute Respiratory Disease[2] Extracorporeal membrane oxygenation	ion (ECMO)						

Line List of Close Contact of a Confirmed Case (page 1 of 1)

Minimum data required for the daily close contact line list:

caseID of index case (if no ID assigned by NIS PHE, name and DOB of index case) ContactID (Local HPzone ID) FirstName LastName Sex (M/F) DOB (dd/mm/yyyy) Telephone number typeContact (HCW/relative or friend/other) placeContact (hospital name/household/other setting) respiratorySymptoms - (Y/N) symptomsOnset (dd/mm/yyyy) dateFirstContact (dd/mm/yyyy) dateLastContact (dd/mm/yyyy) form2a completed - initial questionnaire (Y/N) form2b completed - follow-upQuestionnaire (Y/N) baselineSerumCollected (Y/N) follow-upSerumCollected - day14 (Y/N) baselineSwabsTaken (Y/N) OBS (any relevant remarks) Follow up status (active/passive)

You may copy and transpose the fields into an Excel spreadsheet and use to populate the Contact Line List and email to respiratory.lead@phe.gov.uk

Initial Confirmed Case Report Form 1a (page 19 of

Initial Confirmed Case Report Form - 1a v7- Wuhan

For reference only (Colindale use)									
Confirmed case number (issued by National i.e NIS HPZone)			FF100 id number (automatically generated on FF100 web tool under "contact id")						
*Mandatory fields in pink with bold text and an asterisk									
For multiple choice please mark selected options with an x									
1. Current Status									
*Please mark x	Alive		Dead						
2. Further Case Classification									
*Please mark x	Imported	Secondary	Sporadic						
	3. F	Reporter Details							
*Name of the reporter (person									
completing the form) Date Reported									
Position									
Organisation									
Phone and extension									
Mobile									
Email									
Fax									
Date of interview with informant									
		nformant Details	1						
Informant (Please mark x)	Case		Other						
		If Other:							
Contact details including telephone number									
Relationship with case									
	5.	Patient Details							
NHS number									
*Forename									
*Surname									
Sex	Male	Female	Not Specified						
*Date of Birth			Age						
Local ID Number (HPZone number)			•						

Initial Confirmed Case Report Form 1a (page 20 of

Initial Confirmed Case Report Form - 1a v7- Wuhan

Street Address			Home Telephone	
Town			Work Telephone	
County			Mobile	
Post Code			Email address	
Preferred mode of contact				
Country of Residence			Nationality	
Country of Birth				
*Responsible PHE Centre		•		
Local Authority				
Name of school if appropriate				
Is the case part of an institutional	Yes	No	Unknown	
outbreak?				
If yes, please specify:				
Occupation	HCW	Other	If other please specify	
	Job title		Place of work	
If HCW:		ct patient contact	Place of work Yes	No
If HCW:	Dire	ct patient contact with a case n clinical contact)		No
If HCW:	Dire (eg hands-or	with a case		No
If HCW:	Dire (eg hands-or	with a case n clinical contact)		No
	Dire (eg hands-or	with a case n clinical contact)		No
Name of GP	Dire (eg hands-or	with a case n clinical contact)		No
Name of GP Practice Name	Dire (eg hands-or	with a case n clinical contact)		No

Initial Confirmed Case Report Form 1a (page 21 of

Initial Confirmed Case Report Form - 1a v7- Wuhan

v/- wunan								
	7. P	resenting Illness						
Date of first symptom onset				Unknown (x)				
Maximum temperature								
Respiratory symptoms								
Fever or history of Fever (≥38°C)	Yes	If yes, first onset date	No	Unknown				
Runny nose	Yes	If yes, first onset date	No	Unknown				
Sneezing	Yes	If yes, first onset date	No	Unknown				
Cough	Yes	If yes, first onset date	No	Unknown				
	If yes, dry	or productive?	Dry	Productive				
Shortness of breath	Yes	If yes, first onset date	No	Unknown				
Sore throat	Yes	If yes, first onset date	No	Unknown				
	•	<u> </u>						
		ther symptoms	110100000000					
Diarrhoea	Yes	No	Unknown	_				
Nausea	Yes	No	Unknown					
Vomiting	Yes	No	Unknown					
Fatigue	Yes	No	Unknown					
Muscle ache	Yes	No	Unknown					
Joint ache	Yes	No	Unknown					
Loss of appetite	Yes	No	Unknown					
Headache	Yes	No	Unknown					
Seizures	Yes	No	Unknown					
Altered Consciousness	Yes	No	Unknown					
Nose bleed	Yes Yes	No No	Unknown	-				
Rash				Diagon and alfa-				
Other	Yes	No	-	Please specify				

Initial Confirmed Case Report Form 1a (page 22 of

Initial Confirmed Case Report Form - 1a v7- Wuhan

8. Clinical Course/Complications								
Mechanical ventilation	Yes	If yes, date started	No	Unknown				
ICU Admission	Yes	If yes, date	No	Unknown				
ARDS ¹	Yes	If yes, date diagnosed	No	Unknown				
ECMO ²	Yes	If yes, date started	No	Unknown				
Chest X-ray with pneumonia	Yes	No	Unknown					
Chest A-ray with pheumonia								
Prognancy	Yes	No	Unknown					
Pregnancy								
[1] Acute Respiratory Distress Syndrome								
[2] Extracorporeal membrane oxygenat	on (ECIVIO)							

Initial Confirmed Case Report Form 1a (page 5 of 10)

Initial Confirmed Case Report Form - 1a v7- Wuhan

9. Exposures in the 14 days before onset of first symptoms								
In the 14 days before illness onset did the case travel (both INSIDE OR OUTSIDE the UK)?		No	Unknown					
OUTSIDE the OK)?		s before illness ons	et where did the case	e travel (including travel WITHIN AND OUTS	DE the UK)?			
Location visited	Date of arrival	Date of departure	Arrival mode of transport	Arrival travel details (eg flight/coach number/times, ports of departure/arrival)	Departure mode of transport	Departure travel details (eg flight/coach number/times, ports of departure/arrival)		

Initial Confirmed Case Report Form 1a (page 24 of

Initial Confirmed Case Report Form - 1a v7- Wuhan

In the 14 days before onset did the case have close contact with a	Yes	No	Unknown		
confirmed or probable case while the case was symptomatic?					
Details of Case Contact (if known):	First name		Last name		
Details of Case Contact (II Known).	Age		Date of contact with case		
Setting of contact	Household	Health care setting	School	Aircraft	
	Other, please specify				
In the 14 days before	onset did the	case have close c	ontact with any of tl	ne following?	
Birds (including poultry and all other	Yes	No	Unknown		
avian species)					
Bats	Yes	No	Unknown		
Data					
Civets	Yes	No	Unknown		
Civets					
	Yes	No	Unknown	If yes, please	specify
Other animals (please specify)					

Initial Confirmed Case Report Form 1a (page 25 of

Initial Confirmed Case Report Form - 1a v7- Wuhan

10. Medical History Does the case have any underlying medical conditions? Complete where appropriate This information is collected to understand whether specific groups are at greater risk of infection with this virus, to inform future health advice and precautions. Yes No Unknown Details Chronic heart disease Details Yes Unknown No Diabetes Yes No Unknown Details HIV/other immunodeficiency Yes Unknown Details No Chronic kidney disease Yes No Unknown Details Chronic liver disease Details Unknown Yes No Chronic respiratory disease, excluding asthma requiring medication Unknown Details Yes No Asthma requiring medication Yes No Unknown Details Malignancy Details Yes No Unknown Organ or bone marrow recipient Yes Unknown Details No Seizure disorder Yes No Unknown Details Chronic neurological disease Yes Unknown No Currently pregnant If yes, First Second Third trimester If yes, estimated delivery date Height in cm Weight in kg Other, please specify

Initial Confirmed Case Report Form 1a (page 26 of

Initial Confirmed Case Report Form - 1a v7- Wuhan

11. Treatment with antivirals								
Did the case receive antivirals in the last 14 days?								
Ribavirin	Yes	No	Unknown	Date started	Date started not known (x)			
Other	Yes	No	Unknown	Date started	Date started not known (x)			
If other, please specify								
	12. Hea	althcare Interacti	ons					
Has the case had interaction with any o	f the following	healthcare setting	gs during current illr	ness?				
NHS 111	Yes	No	Unknown	Date of co	ntact			
III CHN								
	Yes	No	Unknown					
Visit to GP								
	If yes, plea	ase specify date(s	s) of GP contact					
	Yes	No	Unknown					
Visit to A&E								
	If yes, plea	se specify date(s) of A&E contact					
	Yes	No	Unknown					
Admitted to hospital								
	С	Date(s) of hospital	Name of hospital	Postcode of hospital				

Initial Confirmed Case Report Form 1a (page 9 of 10)

Initial Confirmed Case Report Form - 1a v7- Wuhan

			13. Test R	esults				
Virological tests								
Specimen Date	Laboratory Test Date	Specimen Type ³		Local Lab Number	Virus	Type of Test ⁵	Result (equivocal, negative, positive)	
] Specimen Types: BAL, E	Blood-Plasma, Blood-Serum, F	aeces, Nose/Throat swa	ıb, NPA, Sputum, Tissue, Oral fluid	, Finger prick, Urine, E	indotracheal aspirate			

[4] Lab Names: Belfast, Birmingham, Bristol, Cambridge, Cardiff, Dublin, Glasgow, Leeds, Leicester, Liverpool, London-Barts, London-Kings, London-St Thomas's, London-UCLH, Manchester, Newcastle, Nottingham, PHE-RVU, Porton, Southampton, Other (please specify)

[5] Test Types: RT-PCR, Sequencing, Pyrosequencing, Antigenic-typing, Phenotypic antiviral susceptibility testing, HA/MN

Initial Confirmed Case Report Form 1a (page 10 of 10)

Initial Confirmed Case Report Form - 1a v7- Wuhan

Has baseline serology been taken on	Yes	No	Not sure	
case?				
If yes, date serology taken?				
Laboratory Name				
Date serology sent to a PHE lab				

Follow-up of Confirmed Case Form 1b (page 29 of

Case follow-up form - 1b v2- Wuhan

	F	or reference only	,			
Confirmed case number (issued by National i.e NIS HPZone)			FF100 id number (automatically generated on FF100 web tool under "contact id")			
*Mand	atory fields in	pink with bold to	ext and an aster	isk		
For multiple choice please mark selected options with an x						
1. Patient Details						
NHS number						
*Forename						
*Surname						
*Date of Birth						
	2.	Reporter Details	F			
*Name of the reporter (person completing the form)						
Date Reported						
Position						
Organisation						
Phone and extension						
Mobile						
Email						
Fax						
Date of interview with informant						
	3.	Informant Details	S			
Informant (Please mark x)	Case		Other			
		If Other:				
Contact details including telephone number						
Relationship with case						

Follow-up of Confirmed Case Form 1b (page 30 of

Case follow-up form - 1b v2- Wuhan

4. Outcome/Status at day 14 post symptom onset (if other specify)							
Please complete only if has been ill or is currently ill.							
Status	Recovered	If recovered. Date symptoms resolved (able to resume normal activities)	ill	Dead	If dead, date of death		
Was the case hospitalised?	Yes	No	Don't know				
was the case hospitalised?	163	NO	Don't know				
If hospitalisation occurred:	Is the case	Yes	No	Don't know			
	still hospitalised?						
	If yes, date of admission						
		Date of discharge ank if patient is still hospitalised)					
If Dead:	Contribution		nderlying/primary				
(n.b. If this information is not currently available, please leave blank	death (mark x		outing/secondary				
and send through an update as soon as	,	No con	tribution to death				
results are known)			Unknown				
	Was a post mortem performed?	Yes	No	Don't know			
		f death as MCCD					
		cause of death)					
	Result o	of coroner's report where applicable					

Follow-up of Confirmed Case Form 1b (page 31 of

Case follow-up form - 1b v2- Wuhan

v2- Wuhan							
		5. Symptoms					
Maximum temperature (°C)							
Respiratory symptoms							
Fever or history of Fever (≥38°C)	Yes	If yes, first onset date	No	Unknown			
Runny nose	Yes	If yes, first onset date	No	Unknown			
Sneezing	Yes	If yes, first onset date	No	Unknown			
Cough	Yes	If yes, first onset date	No	Unknown			
	If yes, dry	or productive?	Dry	Productive			
Shortness of breath	Yes	If yes, first onset date	No	Unknown			
Sore throat	Yes	If yes, first onset date	No	Unknown			
		Other symptoms					
Diarrhoea	Yes	No No	Unknown				
Nausea -	Yes	No	Unknown				
Vomiting	Yes	No	Unknown				
Fatigue	Yes	No	Unknown				
Muscle ache	Yes	No	Unknown				
Joint ache	Yes	No	Unknown				
Loss of appetite	Yes	No	Unknown				
Headache	Yes	No	Unknown				
Seizures	Yes	No	Unknown				
Altered Consciousness	Yes	No	Unknown				
Nose bleed	Yes	No No	Unknown				
Rash	Yes	No	OHKHOWH	Please specify			
Other	165	140		i louse specify			

Follow-up of Confirmed Case Form 1b (page 32 of

Case follow-up form - 1b v2- Wuhan

v2- Wuhan								
6. Clinical Course/Complications								
Mechanical ventilation	Yes	If yes, date started	No	Unknown				
	Yes	If you date	No	Unknown				
HDU/ICU Admission	res	If yes, date	NO	OTIKITOWIT				
ARDS ¹	Yes	If yes, date of diagnosis	No	Unknown				
ECMO ²	Yes	If yes, date started	No	Unknown				
Chest X-ray with pneumonia	Yes	No	Unknown					
Pregnancy	Yes	No	Unknown					
[1] Acute Respiratory Distress Syndrom	e (F0140)							
[2] Extracorporeal membrane oxygenati		dary Bacterial Inf	ections					
		men site	ections					
Date of sample	Positive Results Haemophilus influenzae / MRSA / Staphylococcus aureus / Streptococcus pneumoniae / E. coli / Other organism (please specify)							

Follow-up of Confirmed Case Form 1b (page 5 of 6)

Case follow-up form - 1b v2- Wuhan

9. Reference Test Results							
Virological tests							
Specimen Date	Laboratory Test Date	Specimen Type ³	Lab Name ⁴	Local Lab Number	Virus	Type of Test ⁵	Result

[3] Specimen Types: BAL, Blood-Plasma, Blood-Serum, Faeces, Nose/Throat swab, NPA, Sputum, Tissue, Oral fluid, Finger prick, Urine, Endotracheal aspirate

[4] Lab Names: Belfast, Birmingham, Bristol, Cambridge, Cardiff, Dublin, Glasgow, Leeds, Leicester, Liverpool, London-Barts, London-Kings, London-St Thomas's, London-UCLH, Manchester, Newcastle, Nottingham, PHE-RVU, Porton, Southampton, Other (please specify)

[5] Test Types: RT-PCR, Sequencing, Pyrosequencing, Antigenic-typing, Phenotypic antiviral susceptibility testing, HA/MN

Follow-up of Confirmed Case Form 1b (page 6 of 6)

Case follow-up form - 1b v2- Wuhan

Has convalescent serology been taken on case?	No	Not sure	
If yes, date serology taken?			
Laboratory Name			
Date serology sent to a PHE lab			

Initial Contact Report Form 2a (page 35 of

Initial Contact Report Form - 2a v7- Wuhan

For reference only							
Confirmed case number (issued by National i.e NIS HPZone)		Local ID of contact (local HPZone ID for contact)		FF100 id number (automatically generated on FF100 web tool)			
Name of confirmed case	•						
*Manda	atory fields in p	ink with bold te	xt and an asteris	k			
	1. R	eporter Details					
*Name of the reporter (person completing the form)							
*Date Reported							
Position							
Organisation							
Phone and extension							
Mobile							
Email							
Fax							
*Date of interview with informant							
		formant Details					
Informant (Please mark x)	Contact		Other				
		If Other:					
Contact details including telephone number							
Relationship with contact							
	3. Deta	ails of the Conta	ct				
NHS number							
*Forename							
*Surname							
Sex	Male	Female	Not Specified				
Date of Birth			Age				
Local ID Number (HPZone number)							
Street Address			Home Telephone				
Town			Work Telephone				
County			Mobile				
Post Code			Email address				
Preferred mode of contact							
Country of Residence			Nationality				
Country of Birth							

Initial Contact Report Form 2a (page 36 of

Initial Contact Report Form - 2a v7- Wuhan

*Responsible PHE Centre					
Local Authority					
Name of school if appropriate					
*Location of contact with confirmed case	Household	Health care setting	School	Aircraft	
	Other, please specify				
*Date of last contact with confirmed case (i.e. date of exposure (protected or unprotected) if still in contact please put today's date). This date MUST be included for the daily follow up					
	Yes	No	Unknown		
Is the case part of an institutional outbreak?					
outs out.	If yes, please specify:				
Occupation					
*Healthcare Worker (HCW) working with confirmed case	Yes	No			
	If Yes HCW, pl	ease complete S	ections 4,5 and	6	
	If Not HCW, pl	ease complete S	ections 4,5 and	7	
	4. Syn	nptoms in Conta	ct		
*Has the contact been ill within the 14 days after exposure to the	Yes	No			
confirmed case?					
*Is the contact currently ill?	Yes	No			
	If contact has	not been ill place	ne go to Cootie a	5	
		not been in pleas	se go to Section	1	
Date of first symptom onset				Unknown (x)	
Maximum temperature					

Initial Contact Report Form 2a (page 37 of

Initial Contact Report Form - 2a v7- Wuhan

v/- wunan								
Respiratory symptoms								
Fever or history of Fever (≥38°C)	Yes	If yes, first onset date	No	Unknown				
Runny nose	Yes	If yes, first onset date	No	Unknown				
Sneezing_	Yes	If yes, first onset date	No	Unknown				
Cough	Yes	If yes, first onset date	No	Unknown				
	If yes, dry o	or productive?	Dry	Productive				
Shortness of breath_	Yes	If yes, first onset date	No	Unknown				
Sore throat	Yes	If yes, first onset date	No	Unknown				
		the way man to make						
	Yes	ther symptoms	Unknown					
Diarrhoea -	res	No	Unknown					
Nausea -	Yes	No	Unknown					
Vomiting –	Yes	No	Unknown					
Fatigue -	Yes	No	Unknown					
Muscle ache-	Yes	No	Unknown					
Joint ache	Yes	No	Unknown					
Loss of appetite	Yes	No	Unknown					
Headache-	Yes	No	Unknown					
Seizures -	Yes	No	Unknown					
Altered Consciousness	Yes	No	Unknown					
Nose bleed	Yes	No	Unknown					
Rash-	Yes	No	Unknown					
Other	Yes	No		Please specify				

Initial Contact Report Form 2a (page 38 of

Initial Contact Report Form - 2a v7- Wuhan

5. Medical History Does the contact have any underlying medical conditions? Complete where appropriate This information is collected to understand whether specific groups are at greater risk of infection with this virus, to inform future health advice and precautions. Details Yes No Unknown Chronic heart disease Yes No Unknown Details Diabetes Details Yes No Unknown HIV/other immunodeficiency Yes Unknown Details No Chronic kidney disease Details Yes No Unknown Chronic liver disease Yes No Unknown Details Chronic respiratory disease, excluding asthma requiring medication Details Yes Unknown No Asthma requiring medication Details Yes No Unknown Malignancy Details Yes Unknown No Organ or bone marrow recipient Yes No Unknown Details Seizure disorder Yes No Unknown Details Chronic neurological disease Unknown Yes No Currently pregnant If yes First Second Third trimester If yes, estimated delivery date Height in cm Weight in kg Other, please specify

Initial Contact Report Form 2a (page 39 of

Initial Contact Report Form - 2a v7- Wuhan

6. Exposure in a healthcare setting						
Was any contact with the confirmed	Yes	No				
case unprotected (without full PPE)?						
	First da	ite of unprotected contact				
	Last date of un	protected contact				
Was any contact with the confirmed	Yes	No				
case protected (full PPE)?						
	First date of	protected contact				
	Last date of	protected contact				
Job title						
Place of work						
Direct patient contact?	Yes	No				
(eg Hands-on clinical contact)						
What type of protective ed		1	1	ase and how often	1?	
Surgical mask	Yes	No	Don't know			
	If yes, how often		Often (>50% of time)	Infrequent (<50% of time)	Never	
High filtration mask (FFP3)	Yes	No	Don't know			
	If yes, how often	Aiways	Often (>50% of time)	Infrequent (<50% of time)	Never	
	Yes	No	Don't know			
Eye protection	1000000					
	If yes, how often	/ 11 VV CI y S	Often (>50% of time)	Infrequent (<50% of time)	Never	
Gloves	Yes	No	Don't know			
	If yes, how	NY 1				
	often	/ \ii \v \ci y \ci	Often (>50% of time)	Infrequent (<50% of time)	Never	
			D 11:			
Gown	Yes	No	Don't know			
	If yes, how often		Often (>50% of time)	Infrequent (<50% of time)	Never	
		1				

Initial Contact Report Form 2a (page 40 of

Initial Contact Report Form - 2a v7- Wuhan

Was the contact present while any aerosol generating procedures took place?	Yes	No					
If yes, what procedure were they present at?	Procedure 1			Date			
List and date if more than one	Procedure 2			Date			
	Procedure 3			Date			
Was the contact wearing any type of mask at		Surgical	FFP3	None			
this/these procedure?	Procedure 1						
	Procedure 2						
	Procedure 3						
Date of illness onset for confirmed case (if known)							
E.g. 0 means contact on the	If date of onset in confirmed case is known: Please mark with x below all days of contact with the confirmed case since onset of illness in the confirmed case. E.g. 0 means contact on the day of onset of illness. +1 means contact the day after onset of illness If date of onset in confirmed case is not known please skip to next question						
Day	0	1	2	3	4		
Date							
Enter x for contact occurred on this							
day							
Day	5	6	7	8	9		
	5	6	7	8	9		
Day	5	6	7	8	9		
Day Date Enter x for contact occurred on this	5	6	7	8	9		
Day Date Enter x for contact occurred on this day							
Day Date Enter x for contact occurred on this day Day Date Enter x for contact occurred on this day							
Day Date Enter x for contact occurred on this day Day Date Enter x for contact occurred on this							

Initial Contact Report Form 2a (page 41 of

Initial Contact Report Form - 2a v7- Wuhan

7. Exposure Information - Non Healthcare Workers					
Has the contact been in continuous	Yes	No	Unknown		
contact with the confirmed case? E.g. same household					
Same nousenola					
	If no date of	L f first contact with			
	ii iio, dato o	case			
Last date of contact			Contact has not		
with confirmed case			ended (x)		
Date of illness onset for confirmed					
case (if known)					
Please mark with x below all days E.g. 0 means contact on th If date of onset in	of contact with e day of onset o	of illness. +1 mear	e since onset of il ns contact the day	after onset of illne	
Day	0	1	2	3	4
Date					
Enter x for contact occurred on this day					
Day	5	6	7	8	9
Date					
Enter x for contact occurred on this day					
Day	10	11	12	13	14
Date					
Enter x for contact occurred on this day					
If date of onset in confirmed case is not known, please give the total number of days you were in contact with the confirmed case while they were symtomatic					
Monitoring state of contact following initial assessment	Active		Passive		

Initial Contact Report Form 2a (page 42 of

Initial Contact Report Form - 2a v7- Wuhan

	** ************************************							
8. Outcome/Current Status of Contact								
Please complete only if has been ill or is currently ill.								
Status	Recovered	If recovered. Date symptoms resolved (able to resume normal activities)	ill	Dead	If dead, date of death			
If hospitalisation occurred:	Is the contact	Yes	No	Don't know				
	hospitalised?							
	If yes, date of admission							
		Date of discharge (leave blank if patient is still hospitalised)						
Case classification of contact if appropriate (see below for definitions)	3020 00	Presumptive positive	Possible	Discarded	N/A			
	PHE National Reference Laboratory (RVU) Colindale positive confirmation of infection with novel-CoV	PHE novel-CoV Testing Laboratory positive of infetion with novel-CoV	Acute respiratory infection or more severe illness as per possilbe case algorithm	Any possible case with a negative novel- CoV laboratory result	Not applicable			

Initial Contact Report Form 2a (page 9 of 10)

Initial Contact Report Form - 2a v7- Wuhan

9. Virological Tests (if appropriate)							
Confirmed case number (issued by National i.e NIS HPZone)	Laboratory Test Date	Specimen Type ³	Lab Name ⁴	Local Lab Number	Virus	Type of Test ⁵	Result

[3] Specimen Types: BAL, Blood-Plasma, Blood-Serum, Faeces, Nose/Throat swab, NPA, Sputum, Tissue, Oral fluid, Finger prick, Urine, Endotracheal aspirate

[4] Lab Names: Belfast, Birmingham, Bristol, Cambridge, Cardiff, Dublin, Glasgow, Leeds, Leicester, Liverpool, London-Barts, London-Kings, London-St Thomas's, London-UCLH, Manchester, Newcastle, Nottingham, PHE-RVU, Porton, Southampton, Other (please specify)

[5] Test Types: RT-PCR, Sequencing, Pyrosequencing, Antigenic-typing, Phenotypic antiviral susceptibility testing, HA/MN

Initial Contact Report Form 2a (page 10 of 10)

Initial Contact Report Form - 2a v7- Wuhan

Has baseline serology been taken on	 No	Not sure	
contact?			
If yes, date serology taken?			
Laboratory Name			
Date serology sent to a PHE lab			

Follow-up of Contact Form 2b (page 45 of

Initial Contact Report Form - 2b v2- Wuhan

	Foi	r reference only		
Confirmed case number (issued by National i.e NIS HPZone)		Local ID of contact (local HPZone ID for contact)		FF100 id number (automatically generated on FF100 web tool)
Name of confirmed case				
*Mand	atory fields in p	oink with bold tex	t and an asteris	k
	1. Det	ails of the Conta	ct	
NHS number				
*Forename				
*Surname				
*Date of birth				
	2. F	Reporter Details		
*Name of the reporter (person completing the form)				
*Date Reported				
Position				
Organisation				
Phone and extension				
Mobile				
Email				
Fax				
*Date of interview with informant				
	3. Ir	nformant Details		
Informant (Please mark x)	Contact		Other	
		If Other:		
Contact details including telephone number				
Relationship with contact				

Follow-up of Contact Form 2b (page 46 of

Initial Contact Report Form - 2b v2- Wuhan

	4. Exp	osure Informatio	on					
*Last date of contact with confirmed case (If still in contact put today's date)			Contact has not ended (x)					
Date of illness onset for confirmed case (if known)								
If date of onset in confirmed case is known: Please mark with x below all days of contact with the confirmed case since onset of illness in the confirmed case. E.g. 0 means contact on the day of onset of illness. +1 means contact the day after onset of illness If date of onset in confirmed case is not known please skip to next question								
Day	0	1	2	3	4			
Date								
Enter x for contact occurred on this day								
Day	5	6	7	8	9			
Date								
Enter x for contact occurred on this day								
Day	10	11	12	13	14			
Date								
Enter x for contact occurred on this day								
If date of onset in confirmed case is not known, please give the total number of days you were in contact with the confirmed case while they were symtomatic	5							

Follow-up of Contact Form 2b (page 47 of

Initial Contact Report Form - 2b v2- Wuhan

4. Symptoms in this contact (final updated)							
*Has the contact been ill within the 14 days after exposure to the confirmed case?	Yes	No					
(see symptoms)							
*Is the contact currently ill?	Yes	No					
Did the contact have any additional sym with confirmed case?	ptoms not prev	iously mentioned	in form 2a and up	to 14 days since l	ast exposure		
If yes, date of first symptom onset				Unknown (x)			
If yes, time of onset	AM	PM	Unknown				
If yes, maximum temperature (°C)							
	Resp	iratory symptom	s				
Fever or history of Fever (≥38°C)	Yes	If yes, first onset date	No	Unknown			
Runny nose	Yes	If yes, first onset date	No	Unknown			
Sneezing	Yes	If yes, first onset date	No	Unknown			
Cough	Yes	If yes, first onset date	No	Unknown			
	If yes, dry o	or productive?	Dry	Productive			
Shortness of breath	Yes	If yes, first onset date	No	Unknown			
Sore throat	Yes	If yes, first onset date	No	Unknown			

Follow-up of Contact Form 2b (page 48 of

Initial Contact Report Form - 2b v2- Wuhan

Other symptoms						
	Yes	No	Unknown			
Diarrhoea-	162	NO	UIKIIOWII			
				_		
Nausea -	Yes	No	Unknown			
.,,,,,,,						
Vomiting	Yes	No	Unknown			
volinting						
	Yes	No	Unknown	1		
Fatigue						
	Yes	No	Unknown	1		
Muscle ache-	100	110	- CHIKHOWH			
	V	NI-	University	-		
Joint ache	Yes	No	Unknown			
				_		
Loss of appetite	Yes	No	Unknown			
E033 of appointo						
Headache	Yes	No	Unknown			
neadache-						
	Yes	No	Unknown			
Seizures -						
	Yes	No	Unknown	-		
Altered Consciousness	163	NO	Olikilowii	-		
			I I C I C C C C C C C C C C C C C C C C	-		
Nose bleed	Yes	No	Unknown	_		
-						
Rash	Yes	No	Unknown			
Rusii						
	Yes	No		Please specify		
Other						
Culor						

Follow-up of Contact Form 2b (page 49 of

Initial Contact Report Form - 2b v2- Wuhan

	vz- wunan								
	5. Outcome/Current Status of this contact								
Please com	plete only if has	been ill since exp	posure or is currer	ntly ill.	40				
Status	Recovered	If recovered. Date symptoms resolved (able to resume normal activities)	ill	Dead	If dead, date of death				
If hospitalisation occurred:	Is the contact still	Yes	No	Don't know					
	hospitalised?	date of admission							
	Date of discharge (leave blank if patient is still hospitalised)								
If Dead:	Contribution of	U	nderlying/primary						
(n.b. If this information is not currently available, please leave blank	death (mark x in one only)	Contri	buting/secondary						
and send through an update as soon as		in one only)	in one only)	in one only)	in one omy)	in one omy)	No con	tribution to death	
results are known)			Unknown						
	Was a post mortem performed?	Yes	No	Don't know					
		f death as MCCD cate of the cause of death)	I						
	Result of coron	er's report where applicable							

Follow-up of Contact Form 2b (page 50 of

Initial Contact Report Form - 2b v2- Wuhan

		6. Serology			
Has convalescent serology been taken on contact?	Yes	No	Not sure		
If yes, date serology taken?					
Laboratory Name					
Date serology sent to a PHE lab					
535	7. Final c	ontact classifica	ation		
*MAND	ATORY: Please	mark only one l	box in this section	on	
If contact becomes a possible case: (see below for definitions)	Confirmed	Presumptive positive	Possible	Discarded	
	PHE National Reference Laboratory (RVU) Colindale positive confirmation of infection with novel-CoV	PHE novel-CoV Testing Laboratory positive of infetion with novel-CoV	Acute respiratory infection or more severe illness as per possilbe case algorithm	Any possible case with a negative novel-CoV laboratory result	
Asymptomatic contact: No illness					
Contact did not become ill during the 14 days after case exposure (protected/unprotected contact)					
Lost to follow up					
If the contact is lost (non-responsive) during the follow up period					

Appendix A: FF100 Form Completion Guidance

These notes are to provide guidance to those completing the forms. It is suggested that these investigations could be divided into teams – these could include a 'case reporter' team, a 'contact reporter' team and 'go to' team who would liaise with additional data sources other than the case or contact such as hospitals, laboratories etc.

(a) FF100 Initial Case Report Form 1a – This form should be completed predominately by the 'Case' reporter team. This form should be completed as soon as the PHE Centre is notified by the Emergency Operations team at PHE, Colindale.

Section	Sources	Verified against
Case Classification	Case Reporter / EOC Colindale	
Reporter Details	Case Reporter	
Informant Details	Informant	
Patient Details	Informant	
GP Details	Informant	PDS matching (by EOC?)
Presenting illness	Informant	Healthcare provider / review of medical records
Exposures in the 14 days before onset	Informant	
Medical history	Informant	Healthcare provider / GP / review of medical records
Treatment & prophylaxis with antivirals	Informant / interview with healthcare provider	Review of medical records
Hospitalisation	Informant / Hospital	HES
Test results	Testing laboratory	DataMart
Contact Details	Informant	

(b) FF100 Case Follow-Up Form 1b – This form should be completed by the 'Case' reporter team and should be completed 14 days after symptom onset of the case.

Section	Sources	Verified against
Final case classification	Contact Reporter / EOC	
	Colindale	
Reporter details	Contact Reporter	
Informant details	Informant	
Outcome/Status at 14 days post	Informant	ONS mortality, PDS,
symptom onset		GP/Hospital
Illness	Informant	Healthcare provider /
		review of medical records
Clinical Course/Complications	Informant / interview with	Review of medical
	healthcare provider	records
Treatment with antivirals	Informant / interview with	Review of medical
	healthcare provider	records
Treatment with antibiotics	Informant / interview with	Review of medical

Page 51 of 53

	healthcare provider	records
Interaction with NHS	Informant / Hospital	HES
Reference Test Results	Testing laboratory	DataMart
Bacterial Infections	Testing laboratory	Lab-base/MOLIS

(c) FF100 Initial Contact Report Form 2a – This form should be completed by the 'Contacts' reporter team and should be completed after the Initial Case Report from has been completed by the 'Case' Reporter team, ideally within 24 hours.

Section	Sources	Verified against
Reporter Details	Contact reporter	
Informant Details	Informant	
Contact Details	Informant	
Exposure Information	Informant	
Illness in contacts	Informant	Healthcare provider / review of medical records
Outcome/Status	Informant	ONS mortality, PDS, GP / hospital
Case classification	Contact reporter	
Virological Tests	Testing laboratory	DataMart
Medical History	Informant	Healthcare provider / GP / review of medical records

(d) FF100 Contact Follow-Up Form 2b

Section	Sources	Verified against
Reporter Details	Contact reporter	
Informant Details	Informant	
Final Contact Classification	Contact reporter	
Exposure Information	Informant	
Illness in contacts	Informant	Healthcare provider / review of medical records
Clinical Course/Complications	Informant / interview with healthcare provider	Review of medical records
Outcome Status	Informant	ONS, PDS, GP / Hospital

Acknowledgements

	The authors would like to acknowledge all the			οl		
	and past FF100 protocols. Contributors to the	ne current protocol	include Name Redacted			
Name Redacted		, Maria Zambo	on, Name Redacted			
	Our acknowledgement of contributors to past F100 protocols: Richard Pebody, NR					
	NR		. John Watson.			
Name Redacted						
	NR Daniela de Angelis, NR	, Jim McMenami <u>n,</u>	Name Redacted Roland Salmon	,		
	Jonathan Van-Tam, Name Redacted	James Freed,	Name Redacted			
		NR	<u>-</u>			
	Name Redacted , Bharat Pankania, Nick F	hin, Name Redact	ted Ben Cooper, Name Redacte	ed		
	Name Redacted Maria Zambon,	Name Redacted	Oliver Blatchford, NR			
	NR David Goldberg Name Redacted					